CL2015003343A1 - Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. - Google Patents
Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.Info
- Publication number
- CL2015003343A1 CL2015003343A1 CL2015003343A CL2015003343A CL2015003343A1 CL 2015003343 A1 CL2015003343 A1 CL 2015003343A1 CL 2015003343 A CL2015003343 A CL 2015003343A CL 2015003343 A CL2015003343 A CL 2015003343A CL 2015003343 A1 CL2015003343 A1 CL 2015003343A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- therapeutic agent
- hemoglobin
- treatment
- agent based
- Prior art date
Links
- 102000001554 Hemoglobins Human genes 0.000 title abstract 2
- 108010054147 Hemoglobins Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
Abstract
AGENTE TERAPÉUTICO BASADO EN HEMOGLOBINA MODIFICADA PARA TRATAMIENTO DIRIGIDO AL CÁNCER, E IMAGENOLOGÍA DE DIAGNÓSTICO; COMPOSICIÓN FARMACÉUTICA QUE LO COMPRENDE; Y MÉTODO DE PREPARACIÓN.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361822463P | 2013-05-13 | 2013-05-13 | |
US14/275,885 US9636404B2 (en) | 2013-05-13 | 2014-05-13 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015003343A1 true CL2015003343A1 (es) | 2016-08-05 |
Family
ID=51864923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003343A CL2015003343A1 (es) | 2013-05-13 | 2015-11-13 | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. |
Country Status (20)
Country | Link |
---|---|
US (2) | US9636404B2 (es) |
EP (1) | EP3001813B1 (es) |
JP (1) | JP6392855B2 (es) |
KR (1) | KR102013015B1 (es) |
CN (1) | CN105407911B (es) |
AU (1) | AU2014265659B2 (es) |
BR (1) | BR112015028340A2 (es) |
CA (1) | CA2911414C (es) |
CL (1) | CL2015003343A1 (es) |
EA (1) | EA032164B1 (es) |
HK (2) | HK1222574A1 (es) |
IL (1) | IL242422B (es) |
MA (1) | MA38571B1 (es) |
MX (1) | MX362001B (es) |
MY (1) | MY176175A (es) |
PH (1) | PH12015502536B1 (es) |
SA (1) | SA515370134B1 (es) |
SG (1) | SG11201509042YA (es) |
TW (1) | TWI610685B (es) |
WO (1) | WO2014186301A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA38571B1 (fr) * | 2013-05-13 | 2018-10-31 | Vision Global Holdings Ltd | Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
WO2016036794A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
TR201606102A2 (tr) * | 2016-05-10 | 2016-10-21 | Tolgay Tuyan Ilhan | Karin i̇çi̇ uygulanan kanser tedavi̇leri̇nde oksi̇jen konsantrasyonu ölçümü yapabi̇len ve veri̇len oksi̇jen dozaji üzeri̇nde deği̇şi̇kli̇k yapmayi sağlayan ci̇haz |
CA3028589A1 (en) * | 2016-06-21 | 2017-12-28 | Therapure Biopharma Inc. | Hemoglobin-targeted drug delivery for the treatment of cancer |
EP3555627B1 (en) * | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
CN107153771B (zh) * | 2017-05-17 | 2020-06-30 | 许昌学院 | 一种药物分子的同步控制方法及其应用 |
JP7387597B2 (ja) | 2017-07-18 | 2023-11-28 | ヴァーテック・バイオ・インコーポレイテッド | ヘモグロビンを含む代用血液及び作製方法 |
EP3999529A4 (en) * | 2019-07-19 | 2023-07-12 | Cheer Global Limited | HEMOGLOBIN-BASED THERAPEUTIC AGENT |
CN114605338B (zh) * | 2022-05-11 | 2022-10-28 | 深圳厚存纳米药业有限公司 | 一种含尿嘧啶衍生物的纳米粒、核酸纳米复合物及其制备方法和用途 |
CN116068189A (zh) * | 2023-04-07 | 2023-05-05 | 吉林重明生物科技有限公司 | 早期癌检测试剂及其应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
MC2260A1 (fr) * | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
EP0611306B1 (en) * | 1991-11-08 | 1998-07-08 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
CA2188565A1 (en) * | 1994-04-29 | 1995-11-09 | Meera Venkatesh | Thioether compounds for use in preparing bifunctional chelating agents for therapeutic radiopharmaceuticals |
US5998361A (en) * | 1996-10-18 | 1999-12-07 | University Of Maryland At Baltimore | Polymerized hemoglobin |
CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
US20050059576A1 (en) * | 1998-04-30 | 2005-03-17 | Adamson J. Gordon | Targeted delivery of antiviral compounds through hemoglobin bioconjugates |
DE60317303T2 (de) * | 2003-04-17 | 2008-06-19 | Ezio Panzeri | Hämoglobin-Konjugate |
US7235639B2 (en) | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
WO2010059315A1 (en) * | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
US8084581B1 (en) * | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
US20130052232A1 (en) * | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
US20140106004A1 (en) * | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
MA38571B1 (fr) * | 2013-05-13 | 2018-10-31 | Vision Global Holdings Ltd | Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique |
-
2014
- 2014-05-13 MA MA38571A patent/MA38571B1/fr unknown
- 2014-05-13 MX MX2015015555A patent/MX362001B/es active IP Right Grant
- 2014-05-13 CA CA2911414A patent/CA2911414C/en active Active
- 2014-05-13 AU AU2014265659A patent/AU2014265659B2/en active Active
- 2014-05-13 KR KR1020157032973A patent/KR102013015B1/ko active IP Right Grant
- 2014-05-13 EA EA201501065A patent/EA032164B1/ru not_active IP Right Cessation
- 2014-05-13 SG SG11201509042YA patent/SG11201509042YA/en unknown
- 2014-05-13 CN CN201480040021.4A patent/CN105407911B/zh active Active
- 2014-05-13 EP EP14798660.8A patent/EP3001813B1/en active Active
- 2014-05-13 BR BR112015028340A patent/BR112015028340A2/pt not_active Application Discontinuation
- 2014-05-13 US US14/275,885 patent/US9636404B2/en active Active
- 2014-05-13 TW TW103116929A patent/TWI610685B/zh not_active IP Right Cessation
- 2014-05-13 JP JP2016514013A patent/JP6392855B2/ja not_active Expired - Fee Related
- 2014-05-13 MY MYPI2015703946A patent/MY176175A/en unknown
- 2014-05-13 WO PCT/US2014/037749 patent/WO2014186301A1/en active Application Filing
-
2015
- 2015-11-03 IL IL242422A patent/IL242422B/en not_active IP Right Cessation
- 2015-11-05 PH PH12015502536A patent/PH12015502536B1/en unknown
- 2015-11-12 SA SA515370134A patent/SA515370134B1/ar unknown
- 2015-11-13 CL CL2015003343A patent/CL2015003343A1/es unknown
-
2016
- 2016-09-13 HK HK16110826.1A patent/HK1222574A1/zh unknown
- 2016-09-29 HK HK16111399.6A patent/HK1223037A1/zh unknown
-
2017
- 2017-03-27 US US15/469,978 patent/US10322180B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
BR112016022345A2 (pt) | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 | |
EA201591674A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
CL2014002549A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados. | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
DK2986304T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. | |
BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
BR112017009552A2 (pt) | métodos para alvejar o controle transcricional em regiões de super-realçador | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
BR112019006504A2 (pt) | regime de dosagem de avelumabe para o tratamento de câncer | |
BR112016012248A2 (pt) | método de tratamento de nefropatia |